Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
2(33%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
2
33%
Ph phase_3
1
17%
Ph phase_2
2
33%

Phase Distribution

2

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
2(40.0%)
Phase 3Large-scale testing
1(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

6

all time

Status Distribution
Active(2)
Completed(2)
Other(2)

Detailed Status

Completed2
unknown2
Active, not recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
2
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (40.0%)
Phase 22 (40.0%)
Phase 31 (20.0%)

Trials by Status

active_not_recruiting117%
recruiting117%
completed233%
unknown233%

Recent Activity

2 active trials
Showing 5 of 6
unknownphase_3

Exploring Durable Remission With Rituximab in Antineutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis

NCT03942887
active_not_recruitingphase_1

Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma

NCT04613557
completed

A Pharmacoeconomic Study Comparing the Use of Mycophenolate Mofetil or Cyclophosphamide as Induction Therapy in Lupus Nephritis Patients in Egypt

NCT05195086
unknownphase_2

Brentuximab Vedotin in Combination With CHEP in Patient With PTCL

NCT05006664
recruitingphase_1

Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02

NCT04167696
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT03942887Phase 3

Exploring Durable Remission With Rituximab in Antineutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis

Unknown
NCT04613557Phase 1

Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma

Active Not Recruiting
NCT05195086

A Pharmacoeconomic Study Comparing the Use of Mycophenolate Mofetil or Cyclophosphamide as Induction Therapy in Lupus Nephritis Patients in Egypt

Completed
NCT05006664Phase 2

Brentuximab Vedotin in Combination With CHEP in Patient With PTCL

Unknown
NCT04167696Phase 1

Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02

Recruiting
NCT00284336Phase 2

Caelyx Adjuvant in Elderly Breast Cancer

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6